Chiesi Group, one of the world’s leading producers of modern and innovative medical solutions, focuses on several therapeutic areas, including primarily respiratory diseases specialising in the treatment of asthma, cardiovascular diseases, neonatology, musculoskeletal disorders, gastrointestinal disorders and central nervous system disorders.
In an effort to improve the quality of patients’ lives, the company pays particular attention to research and development of technologies aimed at creating effective, safe and convenient medicinal products. It has 4 own research and development centres in Italy, France, the United States and the United Kingdom, employing an international team of over 300 scientists. Another research centre is being built in Parma, Italy.
In 2010, for the second time in a row, Chiesi Group was at the forefront of Italian pharmaceutical companies investing in research and development. The company was also one of the leaders in the international ranking again: it ranks 8th among the largest Italian companies out of all market sectors, and 14th among international pharmaceutical corporations in Europe.
The company has 24 representative offices around the world and is present in 65 countries. The company’s products are manufactured in 3 factories: in Parma, Italy, in Blois-La Chaussée, France, and in Santana de Parnaiba, Brazil.
The history and activities of the Group are closely linked to the Italian company, Chiesi Farmaceutici S.p.A., which has been undergoing a dynamic development process for 75 years. Activities of the Chiesi Group in Central and Eastern Europe are represented and coordinated by Chiesi Pharmaceuticals GmbH with its registered office in Vienna. ?????
It supplies the Polish market with the latest innovative technological medical solutions of the Chiesi Group, especially in the field of respiratory disease treatment.
The offer available on the Polish market include aerosolised medicine in the form of metered-dose inhalers, used to treat asthma and COPD. Chiesi Pharmaceuticals GmbH also offers hospital products in Poland for use in anaesthesia and intensive care, as well as modern medicines used in orthopaedics and rheumatology.
It supplies the Polish market with the latest innovative technological medical solutions of the Chiesi Group, especially in the field of respiratory disease treatment.
The offer available on the Polish market include aerosolised medicine in the form of metered-dose inhalers, used to treat asthma and COPD. Chiesi Pharmaceuticals GmbH also offers hospital products in Poland for use in anaesthesia and intensive care, as well as modern medicines used in orthopaedics and rheumatology.
